TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma
Brief Summary: The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.


Options:
A: Arm Label: Flutiform 250/10 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 250/10 micrograms | Arm Label: Flutiform 50/5 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 50/5 micrograms | Arm Label: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Arm Label: Flixotide pMDI 250 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 micrograms | Intervention Type: DRUG; Name: Flutiform 250/10 micrograms; Assigned to Arm(s): Flutiform 250/10 micrograms | Intervention Type: DRUG; Name: Flutiform 50/5 micrograms; Assigned to Arm(s): Flutiform 50/5 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Assigned to Arm(s): Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 micrograms; Assigned to Arm(s): Flixotide pMDI 250 micrograms
B: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID | Arm Label: MF MDI 200 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) 200 mcg | Arm Label: F MDI 10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: formoterol fumarate 10 mcg | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI) 200 mcg; Assigned to Arm(s): MF MDI 200 mcg BID | Intervention Type: DRUG; Name: formoterol fumarate 10 mcg; Assigned to Arm(s): F MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo BID
C: Arm Label: Symbicort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol (SYMBICORT) pMDI | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide HFA pMDI | Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): Symbicort | Intervention Type: DRUG; Name: Budesonide HFA pMDI; Assigned to Arm(s): Budesonide
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma
Brief Summary: The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone Furoate, Drug: Albuterol/salbutamol | Arm Label: UMEC 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC, Drug: Fluticasone Furoate, Drug: Albuterol/salbutamol | Arm Label: UMEC 31.25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC, Drug: Fluticasone Furoate, Drug: Albuterol/salbutamol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: UMEC; Assigned to Arm(s): UMEC 31.25 mcg, UMEC 62.5 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): Placebo, UMEC 31.25 mcg, UMEC 62.5 mcg | Intervention Type: DRUG; Name: Albuterol/salbutamol; Assigned to Arm(s): Placebo, UMEC 31.25 mcg, UMEC 62.5 mcg
B: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
C: Arm Label: Symbicort; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (SYMBICORT) pMDI | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide HFA pMDI | Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): Symbicort | Intervention Type: DRUG; Name: Budesonide HFA pMDI; Assigned to Arm(s): Budesonide
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate
Brief Summary: The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.


Options:
A: Arm Label: ETN Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN Alone | Arm Label: ETN+MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN+MTX | Intervention Type: DRUG; Name: ETN Alone; Assigned to Arm(s): ETN Alone | Intervention Type: DRUG; Name: ETN+MTX; Assigned to Arm(s): ETN+MTX
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate
Brief Summary: The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
B: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: methotrexate, Drug: Placebo, triple | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: Sulfasalazine, Drug: Hydroxychloroquine, Drug: Placebo, etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Sulfasalazine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo, triple; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo, etanercept; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.

The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.


Options:
A: Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.

The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.


Options:
A: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Drug: alemtuzumab GZ402673 | Intervention Type: DRUG; Name: alemtuzumab GZ402673; Assigned to Arm(s): Alemtuzumab
D: Arm Label: BAF312 10 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 1.25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .5 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 .25 mg/2 mg, BAF312 .5 mg/2 mg, BAF312 1.25 mg/2 mg, BAF312 10 mg/2 mg, BAF312 2 mg/2 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-Weight Polypropylene Mesh for Anterior Vaginal Wall Prolapse: A Prospective Randomized Study
Brief Summary: The purpose of this study is to determine whether reenforcement with polypropylen mesh compared with traditional anterior colporrhaphy for anterior vaginal wall prolapse results in fewer recurrences.


Options:
A: Arm Label: Mesh surgery; Type: EXPERIMENTAL; Interventions: Device: Tensionfree vaginal mesh kit (Prolift) | Arm Label: Conventional vaginal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: classic vaginal prolapse surgery (fascia plication) | Intervention Type: DEVICE; Name: Tensionfree vaginal mesh kit (Prolift); Assigned to Arm(s): Mesh surgery | Intervention Type: PROCEDURE; Name: classic vaginal prolapse surgery (fascia plication); Assigned to Arm(s): Conventional vaginal surgery
B: Intervention Type: DEVICE; Name: Low-weight prolypropylene mesh; Assigned to Arm(s): N/A
C: Arm Label: Anterior colporrhaphy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: anterior vaginal repair (colporrhaphy), Procedure: abdominal paravaginal defect repair | Arm Label: Paravaginal defect repair; Type: ACTIVE_COMPARATOR; Interventions: Procedure: anterior vaginal repair (colporrhaphy), Procedure: abdominal paravaginal defect repair | Intervention Type: PROCEDURE; Name: anterior vaginal repair (colporrhaphy); Assigned to Arm(s): Anterior colporrhaphy, Paravaginal defect repair | Intervention Type: PROCEDURE; Name: abdominal paravaginal defect repair; Assigned to Arm(s): Anterior colporrhaphy, Paravaginal defect repair
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-Weight Polypropylene Mesh for Anterior Vaginal Wall Prolapse: A Prospective Randomized Study
Brief Summary: The purpose of this study is to determine whether reenforcement with polypropylen mesh compared with traditional anterior colporrhaphy for anterior vaginal wall prolapse results in fewer recurrences.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anterior colporrhaphy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Anterior PROLIFT | Intervention Type: PROCEDURE; Name: Anterior colporrhaphy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Anterior PROLIFT; Assigned to Arm(s): 2
B: Arm Label: Anterior Colporrhaphy (sutured repair); Type: PLACEBO_COMPARATOR; Interventions: Procedure: sutured anterior vaginal prolapse repair | Arm Label: Perigee (grafted repair); Type: ACTIVE_COMPARATOR; Interventions: Device: grafted anterior prolapse repair | Intervention Type: DEVICE; Name: grafted anterior prolapse repair; Assigned to Arm(s): Perigee (grafted repair) | Intervention Type: PROCEDURE; Name: sutured anterior vaginal prolapse repair; Assigned to Arm(s): Anterior Colporrhaphy (sutured repair)
C: Intervention Type: DEVICE; Name: Low-weight prolypropylene mesh; Assigned to Arm(s): N/A
D: Arm Label: Mesh surgery; Type: EXPERIMENTAL; Interventions: Device: Tensionfree vaginal mesh kit (Prolift) | Arm Label: Conventional vaginal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: classic vaginal prolapse surgery (fascia plication) | Intervention Type: DEVICE; Name: Tensionfree vaginal mesh kit (Prolift); Assigned to Arm(s): Mesh surgery | Intervention Type: PROCEDURE; Name: classic vaginal prolapse surgery (fascia plication); Assigned to Arm(s): Conventional vaginal surgery

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-Weight Polypropylene Mesh for Anterior Vaginal Wall Prolapse: A Prospective Randomized Study
Brief Summary: The purpose of this study is to determine whether reenforcement with polypropylen mesh compared with traditional anterior colporrhaphy for anterior vaginal wall prolapse results in fewer recurrences.


Options:
A: N/A
B: Intervention Type: DEVICE; Name: Low-weight prolypropylene mesh; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Avaulta (surgical procedure using a mesh implant) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional surgery (anterior repair) | Intervention Type: PROCEDURE; Name: Avaulta (surgical procedure using a mesh implant); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional surgery (anterior repair); Assigned to Arm(s): 2
D: Arm Label: Anterior colporrhaphy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: anterior vaginal repair (colporrhaphy), Procedure: abdominal paravaginal defect repair | Arm Label: Paravaginal defect repair; Type: ACTIVE_COMPARATOR; Interventions: Procedure: anterior vaginal repair (colporrhaphy), Procedure: abdominal paravaginal defect repair | Intervention Type: PROCEDURE; Name: anterior vaginal repair (colporrhaphy); Assigned to Arm(s): Anterior colporrhaphy, Paravaginal defect repair | Intervention Type: PROCEDURE; Name: abdominal paravaginal defect repair; Assigned to Arm(s): Anterior colporrhaphy, Paravaginal defect repair

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis
Brief Summary: Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Etanercept (Enbrel) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Etanercept (Enbrel); Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulphasalazine (SSZ) | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: sulphasalazine (SSZ); Assigned to Arm(s): B
C: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept/placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: etanercept/placebo; Assigned to Arm(s): 2

Answer: A